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Abstract
Backgroud: IL-17
+ T helper cells and Foxp3
+ regulatory T cells are CD4
+ T helper cells with reciprocally regulated
differentiation and function. Their frequency and function vary in patients with chronic hepatitis B. In this study, we
investigated the balance between IL-17
+ T cells and Foxp3
+ regulatory T cells and illustrated their function in the
aggravation of chronic hepatitis B (CHB).
Results: Twenty-six patients with chronic HBV -related liver failure (CLF), thirty-one patients with acute on chronic
HBV-related liver failure (ACLF) and twelve normal controls were enrolled in our study. The expressions of IL-17,
Foxp3, CD4, CD8 and perforin in liver tissue were measured by immunochemistry for the evaluation of liver-
infiltrating lymphocytes. The frequency of liver IL-17
+ T cells on liver inflammatory cells and their proportion in the
total CD4
+ T cell population increased markedly in the ACLF group, while the frquency of Foxp3
+ T cells and their
proportion in the total CD4
+ T cell population did not show a significant difference in the two HBV infection
groups. In addition, the ACLF group showed a dramatically higher IL-17
+ /Foxp3
+ ratio than the CLF group. CD4
+ T
cells increased significantly in the liver of patients with ACLF, compared with those in the liver of patients with
CLF.
Conclusions: Our findings suggest that intrahepatic IL-17
+ T cells play an important role in the development of
chronic HBV and that the imbalance between IL-17
+ and Foxp3
+ T cells in the liver may lead to progression of the
disease but the mechanism should be further explored.
Background
Chronic hepatitis B (CHB) infection affects over 350
million individuals worldwide. It has become a global
health problem due to its manifestation as chronic liver
failure (CLF), acute on chronic liver failure (ACLF), liver
cirrhosis (LC), and primary hepatocellular carcinoma
(HCC)[1,2]. Hepatitis B virus (HBV) is preferentially
hepatotropic, not directly cytopathic, and elicits liver
diseases of different severity [3]. HBV may also cause
sustained liver tissue damage through different path-
ways, including perforin-mediated cytotoxicity and Fas
ligand/Fas-mediated apoptosis, when antiviral immunity
is not vigorous enough to clear the virus [4]. CD8
+ T
cells are the main effector cells for the elimination of
HBV [5]. Thus, the hepatocellular injuries caused by
HBV infection are predominantly immune-mediated
[1,2]. Studies investigating the frequency of intrahepatic
virus-specific CD8
+ T cells have shown that the non-
virus-specific infiltrating CD8
+T lymphocytes participate
in liver damage in HBV infection [6]. The CD4/CD8 T
cell ratio is 1:3.5 for the liver versus 2:1 for blood lym-
phocytes [7], suggesting that the intrahepatic CD4
+ and
CD8
+ T cells may have a specialized role in the patho-
genesis of liver disease through an immune response.
CD4
+ T helper cells perform critical immune func-
tions via the production of distinct cytokine profiles.
Two new subsets of CD4
+ T cells, IL-17
+ T helper cells
(Th17) and Foxp3
+ regulatory T cells (Treg), have been
described [8,9]. Evidence has shown that circulating IL-
17
+ cells are largely accumulated in the livers of CHB
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any medium, provided the original work is properly cited.patients and that their frequency increases with progres-
sion from CHB to ACLF [10,11]. It has been reported
that the increased levels of Treg cells in the blood and
liver of CHB patients correlated with suppression of
HBV antigen-specific T cell effects or responses in vitro
[12]. Treg cells play a part in the control of chronic
inflammatory responses and contribute to pathologic
events in the liver during HBV infection. Th17 cells are
implicated in host defense against a number of microor-
ganisms [13,14], while Treg cells display a suppressive
function in immune responses and inflammatory dis-
eases [15,16]. A balance between Th17 and Treg cells is
crucial for immune homeostasis. However, the variations
in Th17 and Treg cells in the progression of HBV-
related liver failure is still not clear.
Here we considered whether the frequency and ratio
of intrahepatic Th17 and Treg cells were changed or
disordered during the development of HBV-related
ACLF. In this work, we investigated the frequency of IL-
17
+ and Foxp3
+ T cells in the liver tissue of patients
with HBV-related ACLF and CLF by immunochemistry
and analyzed the possible association between the fre-
quencies of IL-17 and Foxp3 positive cells with various
clinical parameters, aiming to understand the mechan-
ism underlying the effects of Th17/Treg cells on the
development of ACLF.
Results
Clinical data of the three groups
Table 1 shows the clinical data of the CLF, ACLF and
NC groups. There were more male than female patients
in the three groups. Patients in the HBV-related CLF
and ACLF groups were younger than those in the NC
group. There was a clear increase in the alanine amino-
transferase (ALT), total bilirubin (Tbil), international
normalized ratio(INR) and MELD score in the CLF and
ACLF groups, compared with those in the NC group.
T h el e v e l so fT b i l ,I N Ra n dM E L Ds c o r ew e r ee v e n
higher in the ACLF group than those in the CLF group
(p = 0.0001, all). The cholesterol (CHOL) level in the
ACLF group was lower than that in the CLF group (p =
0.0001). The hepatitis B e antigen (HBeAg) positive rate
and hepatitis B deoxyribonucleic acid load (HBV DNA
load) were almost the same in the CLF and ACLF
groups (p = 0.225 and 0.678, respectively).
Distribution of IL-17
+ and Foxp3
+ T cells in liver tissues
Immunochemistry staining of IL-17 and Foxp3 in the
liver tissue of the three groups was performed to study
whether the frequencies of IL-17
+ and Foxp3
+ Tc e l l s
and the IL-17
+ /Foxp3
+ ratio varied during the course of
HBV-related ACLF. Foxp3 was distinctly expressed in
the nuclei of the T lymphocytes while IL-17 showed
granular cytoplasmic staining (Figure 1). As shown in
Table 2, a large number of lymphocytes infiltrated the
liver of patients with HBV-related CLF and ACLF. IL-17
+ T cells were mainly located in the portal area of the
liver and could still be found in the lobes, especially in
the necrotic area (Figure 1C). A significantly strong
expression of IL-17
+ T cells was detected in the ACLF
group (median = 3.18%, interquartile range = 2.31%),
compared with that in the CLF group (median = 1.90%,
interquartile range = 0.84%; p = 0.0001). The Foxp3
+ T
cells mainly infiltrated the portal area of the liver (Figure
1E and 1F) in the CLF and ACLF groups and were evi-
dently increased compared to the NC group, but there
were no significant differences between ACLF and CLF
groups. The IL-17
+ /Foxp3
+ ratio was higher in the
ACLF group than in the CLF group (p = 0.004).
The CD4
+ T lymphocytes in the liver tissue of the three
groups were stained to determination of the percentages
of IL-17
+ and Foxp3
+ T cells in CD4
+ T cells. The ACLF
and CLF patients had a higher IL-17
+/CD4
+ ratio than
the NC group, and the IL-17
+/CD4
+ ratio was remarkably
higher in the ACLF group than in the CLF group and NC
groups (p = 0.008 and 0.001, respectively). The Foxp3
Table 1 Clinical characteristics of the subjects
P value
Group(N) ACLF(31) CLF(26) NC(12) ACLF vs CLF ACLF vs NC CLF vs NC
Gender(m/f) 28/3 22/4 7/5
Agea 40.0(5.5) 47.5(7.5) 48(4.75) .039 .013 .694
ALT(IU/L)
a 93(70.5) 45.5(26.8) 19.0(4.87) .061 .00 .000
Tbil(μmol/L)
a 303.4(201.8) 37.15(21.44) 16.4(1.91) .000 .000 .001
CHOL (mmol/L)
a 1.01(0.63) 2.2(0.3) 3.8(0.76) .000 .000 .000
INR
a 2.50(0.48) 1.63(0.34) 0.96(0.06) .000 .000 .000
HBeAg (+/-) 9/22 4/22 NT .225
HBVDNA(+/-) 23/8 18/8 NT .679
MELD score
a 26.49(3.76) 11.39(3.84) 0(0) .000 .000 .000
NT, not detected; ALT, alanine aminotransferase; CHOL, cholesterol; Tbil, total bilirubin; INR, international normalized ratio; HBeAg, hepatitis B e antigen; anti-HBe,
hepatitis B e antibody; HBVDNA, hepatitis B deoxyribonucleic acid load; MELD, Model for End-stage Liver Disease.
aThe medians (interquartile range) of age, ALT, Tbil, CHOL, INR and MELD for each group are shown
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+ ratio increased slightly in the CLF and ACLF
groups but the differences between the three groups were
not statistically significant.
Distribution of CD4
+ T cells, CD8
+ T cells and perforin
+
cells in liver tissues
The staining of CD4, CD8 and perforin was performed
to determine the levels of CD4
+ Tc e l l s ,C D 8
+ Tc e l l s
and perforin
+ cells in the liver. CD4 and CD8 staining
showed a diffuse non-granular cytoplasmic staining pat-
tern while perforin showed a granular cytoplastic stain-
ing pattern (Figures 2, 3). The frequencies of CD4
+ T
cells and perforin
+ cells were significantly increased in
the liver of patients with CLF and ACLF, compared
with those in the NC group. But the frequency of CD8
+
T cells was significantly decreased in the liver of patients
with CLF and ACLF, compared with those in the NC
group. The positive cells mainly infiltrated the portal
areas of the liver.
The frequencies of CD4
+ T cells and perforin
+ cells
were higher in the ACLF patients than those in the CLF
patients but with no statistical difference (p = 0.060 and
p = 0.086, respectively). On the other hand, there were
more CD8
+ T cells in CLF than that in ACLF group but
with no statistical difference (p = 0.054).
Correlation between the frequencies of specific positive
cells and clinical parameters
To explore the possible role of liver infiltrating IL-17
+
and Foxp3
+ T cells in the development of HBV-related
liver failure, we further analyzed the correlation between
the frequencies of specific positive cells and clinical
Figure 1 Liver infiltration of IL17
+ and Foxp3
+ T cells.F o x p 3( ®) was distinctly expressed in the nuclei of lymphocytes (D: NC, E: CLF, F:
ACLF) (×400) while IL-17 (®) showed granular cytoplastic staining (A: NC, B: CLF, C: ACLF) (×400). A large number of lymphocytes infiltrated into
the livers of the CLF and ACLF patients. IL17
+ and Foxp3
+ T cells were mainly located in the portal area of the liver and could still be found in
the lobe, especially in the necrotic area (C). NC, normal control; CLF, HBV-related chronic liver failure; ACLF, HBV-related acute on chronic liver
failure.
Table 2 The medians of parameters and statistic data in the three groups
P value
Group(N) ACLF(31)
a CLF(26)
a NC(12)
a ACLF vs CLF ACLF vs NC CLF vs NC
IL-17(%) 3.18(2.31) 1.90(0.84) 0(1.41) .000 .000 .000
FoxP3 (%) 0.36(0.55) 0.23(0.44) 0.00(1.42) .621 .000 .000
IL17/Foxp3 7.00(10.30) 4.33(4.66) 0.00(1.5) .004 .000 .002
CD4 (%) 60.94(8.77) 57.24(15.06) 45.84(16.22) .060 .000 .000
IL-17/CD4(%) 5.32(4.51) 3.49(2.11) 0(4.92) .008 .001 .019
FoxP3/CD4(%) 0.62(0.93) 0.69(1.06) 1.35(5.11) .215 .937 .577
CD8 (%) 35.90(8.82) 38.71(14.91) 46.38(15.47) .054 .000 .000
Perforin (%) 7.50(4.35) 5.16(3.32) 2.03(4.17) .086 .002 .003
The proportion of positively stained cells on the liver inflammatory cells in five randomly-selected high power fields (hpf, ×400) were analyzed by two
independent observers who were blinded to the clinical data of the liver tissues.
a The frequency and ratio of positive cells in the three groups are expressed as medians (interquartile range).
NC, normal control; CLF, HBV-related chronic liver failure; ACLF, HBV-related acute on chronic liver failure.
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Spearman’s rank correlation analysis. Among the most
commonly used clinical data for patients with HBV
infection, serum HBV load usually represents virus repli-
cation, and serum ALT levels reflect hepatocellular
inflammatory injury. In addition, Tbil and CHOL are
important indexes for measuring the severity of hepatic
injury, and the MELD score is widely used to estimate
liver function in end-stage liver disease.
I nt h eA C L Fg r o u p ,t h ef r e q u e n c yo fI L 1 7
+ Tc e l l s
correlated with Tbil (r = 0.579, p = 0.001), CHOL (r =
-0.394, p = 0.034) and MELD score (r =0 . 3 6 7 ,p =
0.043), and the ratio of IL17
+/Foxp3
+ correlated with
Tbil (r =0 . 4 3 7 ,p = 0.018) (Figure 4). The frequency of
CD8
+ T cells showed no correlation with Tbil and
MELD scores (r = -0.067 and -0.28, respectively). The
frequency of perforin
+ cells correlated with Tbil (r =
0.443, p = 0.023).
Discussion
IL-17 is mainly produced by a distinct subset of CD4
+ T
helper cells called Th17 cells. IL-17 may be a new mar-
ker for the severity of acute hepatic injury since levels
increase in patients with severe acute hepatic injury or
fulminant hepatic failure [17]. Liver infiltration of IL-17
+
T cells has also been found to be positively associated
with the grade of liver inflammation in CHB patients
[11]. In fact, most experimental evidence to date sug-
gests a role for IL-17 family members in the coordina-
tion of local tissue inflammation, mainly via the induced
release of pro-inflammatory and neutrophil-mobilizing
cytokines [18]. It has been found that the frequency of
circulating IL-17
+ T cells increases with disease progres-
sion from CHB to ACLF [10].
To understand whether the frequency of intrahepatic
IL-17
+ T cells increases during the course of HBV-
related ACLF just as the frequency of circulating IL-17
+
T cells does, we performed immunochemistry staining
of IL-17 and CD4 in liver biopsies from 57 patients with
HBV related end-stage liver diseases. The frequency of
intrahepatic IL-17
+ Tc e l l sa n dt h eI L - 1 7
+/CD4
+ ratio
increased significantly in HBV-related ACLF and CLF
patients, and the increase in IL-17
+ T cells positively
correlated with Tbil, CHOL and MELD score. There-
fore, the increase in IL-17
+ T cells can reflect the grade
of hepatic injury during the progression of liver disease.
Inappropriate, excessive, or non-specific IL-17
+ Tc e l l
effector responses may be involved in the pathogenesis
of HBV-related ACLF. However, little is known about
t h er e g u l a t o r yr o l eo fI L - 1 7
+ Tc e l l si nH B Vi n f e c t i o n .
An in vitro study by Li, J et al. has demonstrated that
HBcAg can stimulate the production of IL-10, which
negatively regulates HBcAg-specific Th17 cell responses
in CHB patients [19]. Similar findings in a study of
chronic hepatitis C virus (HCV) has also revealed that
HCV-specific Th1 and Th17 cells are suppressed by
HCV nonstructural protein 4 (NS4) -induced production
of IL-10 and transforming growth factor (TGF)-b [20].
Th17 and Treg, which are two subsets of CD4
+T cells,
share reciprocal developmental pathways in immune
responses. The generation of Treg cells is dependent on
a critical differentiation factor named TGF-b [21]. An
experiment in mice demonstrated that the generation of
Foxp3
+ Treg cells can be completely inhibited by IL-6
induced during inflammation, while the differentiation
of pathogenic Th17 cells from naive T cells is induced
by IL-6 plus TGF-b[22]. Notably, a more recent study
has suggested that Th17 cells play a crucial role in the
Figure 2 Liver infiltration of CD4
+ Tc e l l sa n dC D 8
+ Tc e l l s . CD8 (A: NC, B: CLF, C: ACLF) and CD4 (D: NC, E: CLF, F: ACLF) (×400) showed
diffuse non-granular cytoplasmic staining while perforin showed granular cytoplasmic staining. The positive cells mainly infiltrated into the portal
areas of the liver. NC, normal control; CLF, HBV-related chronic liver failure; ACLF, HBV-related acute on chronic liver failure.
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antigen-specific Treg cells suppress Th17-mediated lung
inflammation [23].
Immunochemistry staining of Foxp3 was used to
determine the number of Treg cells infiltrating the liver
tissue since Foxp3 is not only a transcription factor but
also a specific marker for Treg [24]. Our result showed
that the frequency of Foxp3
+ T cells increased signifi-
cantly in HBV-related ACLF and CLF patients
compared to NC, but there was no significant difference
between the CLF and ACLF patients. Xu et al. have
found that the frequency of Foxp3
+ Treg cells increased
dramatically in the circulation and liver of 9 patients
with chronic severe hepatitis B, and that the increase in
Treg at the inflammatory site is associated with the
chronicity and severity of liver inflammation [12]. Our
finding that Foxp3
+ T cells in the ACLF and CLF
patients were similar is in contrast to that study, prob-
ably because the patients enrolled in our study suffered
from severe and end-stage liver diseases. As a result,
there was a small increase in Foxp3
+ Tc e l l sb u tt h e y
were unable to suppress the inflammation, leading to
massive hepatic necrosis and thereafter, to poor
prognosis.
The IL-17
+/Foxp3
+ ratio in the ACLF patients was
higher than that in CLF patients, which suggests that
the number of IL-17
+ T cells increased and caused
immune hepatic injury in the progression of ACLF.
However, although the numbers of suppressive Foxp3
+
T cells increased a little, they did not reach the same
proportion as the IL17
+ T cells, leading to a relative
shortage of suppressive factors. This suggests that the
imbalance of the IL-17
+/Foxp3
+ ratio in the liver infil-
trating lymphocytes may be the key factor for the devel-
opment of fatal ACLF.
CD8
+ T cells participate in the elimination of HBV
and may cause sustained liver damage [5] while Treg
cells have a negative regulatory function. Previous stu-
dies on chronic hepatitis C have found that human CD4
+ CD25
+ T cells can cause pronounced and sustained
inhibition of CD8
+ T cell proliferation [25,26]. Franzese
et al [27] have found that the frequencies of CD4
+CD25
+Treg cells showed no significant difference in patients
with immunotolerant, chronic active and asymptomatic
HBV infections, while the decrease in CD4
+ CD25
+ T
cell frequency was found in patients with a flare-up of
chronic hepatitis B. An in vitro study showed that deple-
tion of the CD4
+ CD25
+ T cell population affected not
only the expansion of HBV-specific CD8
+ T cells but
also their function [27]. This confirms the ability of cir-
culating CD4
+ CD25
+ T cells to suppress antiviral
immune responses mediated by CD8
+ T cells [25,28].
CD4
+ CD25
+ T cells are activated to suppress the
expansion of HBV-specific CD8
+ T cells, thus preclud-
ing HBV clearance but limiting excessive immune-
mediated liver damage. This regulation is clearly non-
antigen specific [27].
Conclusions
Our study suggests that intrahepatic IL17
+ T cells
played an important role in the development of chronic
hepatitis B and that an imbalance between IL-17
+ and
Foxp3
+ T cells in the liver might lead to progression of
Figure 3 Liver infiltration of perforin
+ cells. Perforin showed
granular cytoplastic staining (A: NC, B: CLF, C: ACLF) (×400). NC,
normal control; CLF, HBV-related chronic liver failure; ACLF, HBV-
related acute on chronic liver failure.
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+ T cells in the
liver-infiltrating lymphocytes of ACLF and CLF patients
was not proportional with the increase in IL-17
+ T cells,
the Foxp3
+ T cells could not negatively regulate the
immune system and ultimately, this would cause liver
failure. We did not study the frequencies of T cell sub-
sets infiltrating into the liver by using more precise
methods such as flow cytometry or study the propor-
tions of these subsets in the peripheral blood simulta-
neously or dynamically. Thus, we do not know the exact
mechanism underlying the effects of the Treg cells on
the Th17 cells and CD8
+ T cells. The function of IL-17
+
T cells and Foxp3
+ T cells in the progression of HBV-
related ACLF should be further explored.
Methods
Subjects
We recruited 57 patients with end-stage liver disease
following liver transplantation at the First Affiliated
Hospital of Medical College, Xi’an Jiaotong University
(Xi’an, China) from January 2002 to June 2009. Patients
were classified into two groups. Twenty-six patients suf-
fered from HBV-related CLF and 31 patients were diag-
nosed with HBV-related ACLF according to the
corresponding diagnostic criteria [29]. We excluded
patients with comorbidities such as hepatitis C infection,
rheumatoid arthritis, autoimmune hepatitis and hepato-
cellular carcinoma according to their clinical
information and histological data. Twelve patients who
had undergone hepatic hemangioma surgery and had
normal liver tissues were used as normal controls (NC).
Patients with viral hepatitis, autoimmune hepatitis and
alcoholic liver diseases were excluded from the normal
controls. The institutional review board of the First
Affiliated Hospital of Medical College, Xi’an Jiaotong
University approved these protocols, and informed con-
sent was obtained from all individuals.
Clinical data of the patients were recorded in detail
and summarized in Table 1. The Model for End-stage
Liver Disease (MELD) score was calculated by the for-
mula: 3.8*loge(bilirubin [mg/dL])+ 11.2*loge(INR) +
9.6*loge(creatinine [mg/dL]) +6.4*(etiology: 0 if chole-
static or alcoholic, 1 otherwise) [30].
Immunohistochemical staining
Paraffin-embedded, formalin-fixed liver tissues were cut
into 5-μm sections and placed on polylysine-coated
slides. Each paraffin section was deparaffinized and
rehydrated through a graded series of ethanol. The anti-
gen retrieval (Table 3) was performed by steaming the
slides in appropriate buffer at different temperatures
and pressures. Endogenous peroxidase was blocked
using a 3%H2O2 methanol solution. 5% bovine serum
albumin was applied to block nonspecific staining. Rat
mAbs for anti-human Foxp3 (eBiosciences, San Diego,
CA), rabbit anti-human IL-17 (Beijing Bioss Biotech,
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Figure 4 Correlation between the frequency of IL17
+ cells, the ratio of IL17+/Foxp3+ and the clinical parameters. The frequency of IL17
+ T cells correlated with Tbil (A, r = 0.579, p = 0.001), CHOL (B, r = -0.394,p = 0.034) and MELD scores (C, r = 0.367, p = 0.043), and the ratio of
IL17+/Foxp3+ correlated with Tbil (D, r = 0.437, p = 0.018).
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Page 6 of 8Beijing, China), rabbit anti-human CD4, CD8 and mouse
anti-perforin (Zymed, San Diego, CA) were used for the
immunochemistry staining of Foxp3, IL-17, CD4, CD8
and perforin, respectively. Incubation of biotin-free sec-
ondary antibody and horseradish peroxidase (Zhongshan
Goldenbridge Biotech, Beijing, China) was subsequently
performed, followed by development with diaminobenzi-
dine (Sigma, St Louis, MO, USA) and counterstaining
with hematoxylin. Negative control staining was per-
formed with cold PBS, instead of the primary antibody.
Data collection of Immunohistochemical staining
Two experienced pathologists separately counted the
number of positive staining in 5 randomly chosen
(×400) high-power fields of view. And the numbers of
the total liver inflammatory cells in the same 5 high-
power fields of view were also counted. Then the fre-
quency of each positive staining on the total liver
inflammatory cells was got. Each pathologist was una-
ware of the clinical diagnosis of the patient associated
with any of the tissue sections at the time of analysis.
Statistical analysis
Results were expressed as medians (interquartile range).
Statistical comparisons between two groups were made
by a Mann-Whitney non-parametric U test. Spearman’s
correlation analysis was performed to evaluate the rela-
tionship between two variables. Data were analyzed
using SPSS version 16.0 for Windows (SPSS Inc., Chi-
cago, IL). P values of < 0.05 were considered significant
for all analyses.
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